Intravesicular Cidofovir for the Management of BK Virus-Associated Cystitis

Hemorrhagic cystitis (HC) is a complication of hematopoietic stem cell transplantation (SCT), occurring in 10% to 70% of transplant recipients [1]. Intensive preparative regimens, especially those including busulfan, high-dose cyclophosphamide or ifosfamide, allogeneic SCT, transplantation from unrelated donors, and graft-versus-host disease (GVHD) are all factors that may contribute to the development of HC [2-4].